Relmada Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) will have its CEO, Sergio Traversa, participate in two virtual investor conferences. The first is the Jefferies London Healthcare Conference on November 19, 2020, at 10:50 AM EST, with a live webcast available on their website. The second is the Piper Sandler 32nd Annual Healthcare Conference, where a fireside chat will be accessible starting November 23, 2020. Relmada specializes in therapies for CNS diseases, focusing on major depressive disorder (MDD) with its lead program REL-1017.

NEW YORK, Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:

Jefferies London Healthcare Conference

Date: Thursday, November 19, 2020
Time: 10:50 AM EST/3:50 PM GMT
Webcast: A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: www.relmada.com.  A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

Piper Sandler 32^nd Annual Healthcare Conference

Management will participate in a fireside chat, which will be accessible beginning on November 23, 2020, via the "Investors" section of the company's website: www.relmada.com. The link will remain active for 90 days thereafter.

About Relmada Therapeutics, Inc. 

Relmada Therapeutics is a late-stage pharmaceutical company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, and is entering late-stage studies as an adjunctive treatment for MDD in adults.

Investor Contact: 
Tim McCarthy 
LifeSci Advisors 
212-915-2564 
tim@lifesciadvisors.com

Media Inquiries: 
FischTank PR
relmada@fischtankpr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-participate-in-upcoming-investor-conferences-301174575.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What is the schedule for Relmada Therapeutics' investor conferences?

Relmada Therapeutics will participate in the Jefferies London Healthcare Conference on November 19, 2020, at 10:50 AM EST and the Piper Sandler 32nd Annual Healthcare Conference starting November 23, 2020.

Where can I watch the live presentation of Relmada Therapeutics at the Jefferies conference?

The live webcast for Relmada's presentation at the Jefferies London Healthcare Conference can be accessed on their website in the 'Investors' section.

What is REL-1017 and how is it related to Relmada Therapeutics?

REL-1017 is Relmada Therapeutics' lead program, a novel NMDA receptor channel blocker being studied as an adjunctive treatment for major depressive disorder.

How long will the webcasts for Relmada Therapeutics' conferences be available?

The webcasts for both conferences will be available for replay for 90 days after the live presentations.